Arkolith/Insider Trading/LYEL/Form 4

Seely Lynn

President and CEO, DirectorLyell Immunopharma, Inc. (LYEL) · full profile →Form 4 · filed Jun 15, 2026
Net Selling
Open-Market Buys
$0
Open-Market Sells
$7K
Net Open-Market Flow
-$7K
Transactions
1
1 non-derivative · 0 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
May 11, 2026Sell(S)388$18.91$7K74K

Transaction Codes

S
Open-market sale

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001327111-26-000003) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML